A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
Background: Carfilzomib is a second-generation proteasome inhibitor (PI) used for combination therapy with dexamethasone and/or lenalidomide in patients with relapsed or refractory multiple myeloma. Reports indicate that PIs have a unique toxicity profile that includes thrombocytopenia as a hematolo...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2024-11-01
|
| Серія: | Therapeutic Advances in Hematology |
| Онлайн доступ: | https://doi.org/10.1177/20406207241292517 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|